Evaxion Biotech A/S (NASDAQ:EVAX) Shares to Reverse Split on Monday, January 13th

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock is scheduled to reverse split on the morning of Monday, January 13th. The 1-5 reverse split was announced on Monday, December 30th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 10th.

Evaxion Biotech A/S Stock Down 1.5 %

Evaxion Biotech A/S stock opened at $0.91 on Friday. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The company’s 50-day moving average is $1.59 and its 200-day moving average is $2.47. The firm has a market capitalization of $5.34 million, a PE ratio of -3.14 and a beta of -0.39. Evaxion Biotech A/S has a fifty-two week low of $0.83 and a fifty-two week high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to the consensus estimate of $0.19 million. Sell-side analysts anticipate that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC purchased a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned 1.00% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.